Με χρονολογική σειρά:

1. Α case of classical (Mediterranean Type) Kaposi’s sarcoma evoluted to AIDS-Kaposi.

M.Hadjivasiliou, N. Stavianeas, E. Koumantaki, V. Paparizos, K. Verros, J.D. Stratigos.

Les Nouvelles Dermatologiques, Vol. 8, No 5, Sept.-Oct. 1989.

2. Coexistence of sarcoidosis with Kaposi’s Sarcoma

N.Stavianeas, V. Paparizos, C.H. Skourtia, P. Stavropoulos, A. Kaloterakis, A. Lioulias, J.D. Stratigos.

Dermatology in Europe. Oxford, Blackwell scientific publications, p. 648-649.

3. Malignant syphilis in HIV-infected patients.

Tosca A, Stavropoulos PG, Hatziolou E, Arvanitis A, Stavrianeas N, Hadjivassiliou M, Stratigos JD
Int J Dermatol. 1990 Oct;29(8):575-8

4. Detection of autoimmunity parameters in the acquired immunodeficiency syndrome (AIDS).

Kyriakis K, Tosca A, Katsantonis J, Hadjivassiliou M, Eliopoulos G, Stratigos J
Int J Dermatol. 1992; 31(2):113-6.


5. Outcome of the opportunistic infections in patients with AIDS in two Greek hospitals: 1989-1994

M.Lazanas, B.Papastamopoulos, V.Paparizos, N.Polydorou, S.Michaliou, M.Chini, N.Stavrianeas, G.Saroglou, J.Stratigos

Eur j Int Med 1995, 6 (suppl 1), Hellenic chapter, p.159

6. Experience with Adriamycin, Bleomycin, Vincristine (ABV) palliative chemotherapy in advanced AIDS-related Kaposi’s sarcoma

V.A.Paparizos, K.P.Kyriakis, K.A.Mileounis, D.Pfandl-Polydorou, N.G.Stavrianeas, A.G.Vareltzidis, J.D.Stratigos

Journal of Chemotherapy, Vol 8-n.5 (403-406), 1996

7. Systemic treatment for AIDS-associated Kaposi’s sarcoma. The experience of Athens University Hospital for Skin.

N.G.Stavrianeas, D.Polydorou, V.Paparizos, I.Zagoreos, E.Potouridou, A.C.Katoulis, A.Katsambas, A.Vareltzidis, J.D.Stratigos.

Skin Cancer, Vol 11, Number 1, January/March 1996 (95-101)

8. Hospital care for persons with AIDS in the European Union

MJ Postma, K.Tolley, RM Leidl, AM Downs, EJ Beck, AM Tramarin, YA Flori, M Santin, F Antonanzas, H Kornarou, V Paparizos, MGW Dijkgraaf, J Borleffs, AJP Luijben, JC Jager (European Research Team on AIDS Scenarios)

Health Policy 1997; 41: 157-176

9. Incidence of herpesviruses infections in HIV(+) patients

N.Stavrianeas, E.Rallis, A.Papanicolaou, V.Paparizos, A.Karalexis, A.Vareltzidis

Journal of the European Academy of Dermatology and Venereology 1997; 9(suppl.1), S227

10. Genotypic characterization of human immunodeficiency virus type 1 in Greece.

Multicentre Study on HIV-1 Heterogeneity.

Nasioulas G, Paraskevis D, Paparizos V, Lazanas M, Karafoulidou A, Hatzakis A

AIDS Res Hum Retroviruses 1998 May 20;14(8):685-690

11. Oral candidosis in HIV-infected individuals in Greece: incidence of Candida spp., Candida albicans serotypes and their susceptibility to antifungal agents.

E.Fragouli, A.Velegraki, A.Athanassopoulou, V.Paparizos, P.Stromboulis, N.J.Legakis

Mycoses 1999; 42(3): 133

12. Re-evaluation of the natural course of bullous pemphigoid. A prospective study.

Kyriakis KP, Paparizos VA, Panteleos DN, Tosca AD

Int J Dermatol 1999 Dec;38(12):909-13

13. An overview of classic Kaposi's sarcoma in Greece.

Stratigos JD, Katoulis AC, Stavrianeas NG.
Adv Exp Med Biol. 1999;455:503-6.

14. Protease inhibitor therapy-associated lipodystophy, hyper-triglyceridemia and diabetes mellitus

V.A.Paparizos, K.P.Kyriakis, C.Botsis, V.Papastamopoulos, M.Hatjivassiliou, N.G.Stavrianeas

AIDS 2000; 14(7): 903-5

15. Hospital care for persons with AIDS in the European-Union countries; a cross-country comparison

MJ Postma, H Kornarou, V Paparizos, RM Leidl, K.Tolley, J. Kyriopoulos, JC Jager.

Health Care Management Science 2000; 3: 1-7

16. Lack of reactivation of CMV-retinitis in an AIDS patient, during and after stopping long term cidofovir treatment

V.Papastamopoulos, C.Botsi, VA Paparizos, KP Kyriakis, J.Zagoreos, NG Stavrianeas

Journal of Chemotherapy 2000; 12(3): 258-60.

17. Epidemiologic characteristics of Koebner phenomenon in AIDS-related Kaposi’s sarcoma (AIDS-KS).

V.A.Paparizos, K.P.Kyriakis, D.Polydorou, M.Hadjivassiliou, N.G.Stavrianeas. J Acquir Immune Defic Syndr 2000 Nov 1; 25(3): 283-4

18. Molecular characterization of a recombinant HIV type 1 isolate (A/G/E/?): Unidentified regions may be derived from parental subtype E sequences.

D.Paraskevis, M.Magiorkinis, V.Paparizos, G.N.Pavlakis, A.Hatzakis

AIDS Res Hum Retroviruses 2000; 16(9): 845-855

19. Epidemiologic characteristics of Koebner's phenomenon in AIDS-related Kaposi's sarcoma.

Paparizos VA, Kyriakis KP, Polydorou-Pfandl D, Hadjivassiliou M, Stavrianeas NG

J Acquir Immune Defic Syndr. 2000; 25(3):283-4.

20. Prevalence of multi-class resistance among antiretroviral-experienced HIV-1 infected patients failing therapy.

D.Paraskevis, E.Magiorkinis, M.Lazanas, P.Gargalianos, M.Hini, V.Paparizos, G.Z.Panos, G,Chryssos, H.Sabatakou, A.Antoniadou, A.Karafoulidou, M.Pappa, G.Touloumi, A.Hatzakis.

AIDS 2000; 14(suppl 4): S117

21. HIV-1 infection-associated risk factors among sexually transmitted disease patients in Athens, Greece: 1990 to 1996.

Kyriakis KP, Hadjivassiliou M
Sex Transm Dis. 2000; 27(5):259-65.

22. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece.

Kyriopoulos JE, Geitona MA, Paparizos VA, Kyriakis KK, Botsi CA, Stavrianeas NG.

J Med Syst. 2001 Feb;25(1):73-80.

23. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1 positive individuals.

G.Touloumi, V.Paparizos, H.Sambatakou, O.Katsarou, G.Chryssos, T.Kordossis, A.Antoniadou, H.Hatzitheodorou, N.Stavrianeas, P.Gargalianos, A.Karafoulidou, M.Lazanas, H.Giamarelou, A.Hatzakis.

HIV Clin Trials 2001; 2(1):6-16

24. Lipodystrophy symdrome in 29 naive patients on combined therapy (highly active antiretroviral therapy) in Greece.

EC Siakavellas, D.Kyriaki, N.Sevastos, V.Paparizos, A.Filiotou, N.Stavrianeas, A.Kaloterakis, N.Katsilabros

Antiviral Therapy 2001; 6(4): 77

25. Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.

Touloumi G, Paparizos V, Sambatakou H, Katsarou O, Chrysos G, Kordossis T, Antoniadou A, Hatzitheodorou H, Stavrianeas N, Gargalianos P, Karafoulidou A, Lazanas M, Giamarelou H, Hatzakis A.
HIV Clin Trials. 2001; 2(1):6-16.


26. The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece.

Kyriopoulos JE, Geitona M, Paparizos VA, Kyriakis KP, Botsi CA, Stavrianeas NG

J Med Syst. 2001; 25(1):73-80.


27. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication.

Hatzakis A, Gargalianos P, Kiosses V, Lazanas M, Sypsa V, Anastassopoulou C, Vigklis V, Sambatakou H, Botsi C, Paraskevis D, Stalgis C
J Interferon Cytokine Res. 2001; 21(10):861-9.


28. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone.

Paparizos VA, Kyriakis KP, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG
J Acquir Immune Defic Syndr. 2002; 30(2):257-8.

29. Mutations associated with genotypic resistance to antiretroviral therapy in treatment naive HIV-1 infected patients in Greece.

Magiorkinis E, Paraskevis D, Magiorkinis G, Chryssou S, Chini M, Lazanas M, Paparizos V, Saroglou G, Antoniadou A, Giamarellou E, Karafoulidou A, Hatzakis A
Virus Res. 2002; 85(1):109-15.

30. Malakoplakia of the lung caused by Pasteurella multocida in a patient with AIDS.

Bastas A, Markou N, Botsi C, Myrianthefs P, Trigidou R, Poulakis N, Polyzogopoulos D

Scand J Infect Dis. 2002;34(7):536-8.


31. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.

Dourakis SP, Sevastianos VA, Alexopoulou A, Deutsch M, Stavrianeas N
J Clin Oncol. 2002; 20(13):3030-2.